Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Pacific Edge signs Cxbladder agreement with MultiPlan

Pacific Edge signs Cxbladder agreement with national provider network MultiPlan in the US

Pacific Edge announced today that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostics laboratory testing. The agreement includes Pacific Edge’s participation in the MultiPlan, PHCS and PHCS Savility Networks.

The agreement is the fourth signed with national provider networks by Pacific Edge since October 2013 and is another step in the Company’s commercial roll-out of Cxbladder in the United States, the world’s largest healthcare market. The agreement with MultiPlan in addition to the agreements with FedMed,
Americas Choice Provider Network, and Stratose makes Cxbladder available to a significant proportion of US residents.

Pacific Edge Chief Executive Officer David Darling says national and regional provider networks are a key component in the commercial fabric ensuring that healthcare providers and technology suppliers are paid by healthcare payers for treatment provided to patients.

“Our participation in these networks will give a large number of Americans access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test that is particularly appealing to US healthcare professionals, patients, and insurers.”

Pacific Edge’s agreement with MultiPlan will give MultiPlan’s participating providers and its clients’ members access to Cxbladder. Approximately 900,000 providers participate in MultiPlan’s provider networks and an estimated 68 million consumers have access to one or more of these networks.

Pacific Edge through its wholly owned subsidiary Pacific Edge Diagnostics USA (PEDUSA) has launched Cxbladder in the US and is processing samples collected using its proprietary Urine Sampling System at its custom built, CAP accredited laboratory in Hershey, Pennsylvania.

“Our sales and marketing teams are now focussed on the urologists and clinicians who are treating the largest number of bladder cancer patients to ensure they fully understand the value and benefits that Cxbladder provides to them and their patients” says Jackie Walker, Chief Executive Officer of PEDUSA.

“In addition we are advancing relationships with large commercial payers and the Centre for Medicare and Medicaid Services (CMS), which provides healthcare insurance for 100 million people or nearly a third of the American population. Progress is being made with key customer segments including Integrated Healthcare Systems, the Veterans Administration (VA), and Large Urology Groups (LUGS),

who are the point of contact for many patients presenting with haematuria blood in the urine) which is an early indicator of possible bladder cancer.”

More than one million Americans a year undergo medical investigation for potential bladder cancer at an estimated cost in excess of US$1 billion. Bladder cancer is one of the most expensive cancers to treat.

The very high recurrence rate of this disease, requiring some patients to receive expensive monitoring for the rest of their lives, causes bladder cancer to have the highest total medical costs of any cancer from detection to death. In the US, the total medical cost approaches US$220,000 per patient.

Ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Gambling: SkyCity First Half Profit Rises 30%, Helped By High Rollers

SkyCity anticipates the Auckland business will benefit from government gaming concessions which were triggered on Nov. 11 in recognition of SkyCity’s $470 million Convention Centre development. Morrison said the concessions would allow the Auckland business to lift its activity during peak period, noting it had a record revenue week over the Christmas and New Year period. More>>

ALSO:

Money For Light: Kiwi Scientists Secure Preferential Access To Synchrotron

Science and Innovation Minister Steven Joyce today announced a three-year investment of $2.8 million in the Australian Synchrotron, the largest piece of scientific infrastructure in the Southern Hemisphere, to secure preferential access for Kiwi scientists. More>>

Telco Industry Report: Investment Hits $1.7 Bln A Year

Investment in the telecommunications sector is $1.7 billion a year, proportionately one of the highest levels in the OECD, according to a report released today on the status of the New Zealand sector. More>>

ALSO:

PGPs: New Programme Sets Sights On Strong Wool

A new collaboration between The New Zealand Merino Company (NZM) and the Ministry for Primary Industries (MPI), announced today, aims to deliver premiums for New Zealand's strong wool sector... More>>

ALSO:

Restrictions Lifted: No Further Tau Flies Found

The Ministry for Primary Industries (MPI) confirms that all restrictions on the movement of fruit and vegetables in Manurewa, Auckland, due to the Tau fly, have been lifted as of 2.26pm on Sunday 7 February. More>>

Crowdfinding: Awaroa Beach To Become Public Land If Appeal Succeeds

Conservation Minister Maggie Barry says a privately-owned beach will become part of the Abel Tasman National Park if an online crowdfunding campaign to buy it succeeds... More>>

ALSO:

Meat Workers Union: Waitangi Mondayisation Flaunted By Large Employer Of Maori

At the AFFCO Talley owned meat plant in Rangiuru, the company has resorted to bullying and threats... saying they could be disciplined and their union sued for an unlawful strike if workers exercise their rights to a paid day off tomorrow. More>>

Earlier:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news